News Releases

News Releases

May 07, 2020
Remain on Track with MYCAPSSA® Anticipated June 26, 2020 PDUFA Date and Planned U.S. Commercial Launch in Q4’20 NEEDHAM, Mass. , May 07, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late-stage biopharmaceutical company focused on improving the lives of patients who face
Apr 30, 2020
Company to host conference call and webcast at 5:00 p.m. ET NEEDHAM, Mass. , April 30, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical, late-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it
Mar 16, 2020
MYCAPSSA ® PDUFA Date Set for June 26, 2020 ; U.S. Commercial Launch Planned in Q4’20 First Industry Sponsored U.S. Disease State Registry for Acromegaly Began Enrolling Patients NEEDHAM, Mass. , March 16, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical stage biopharmaceutical
Jan 10, 2020
MYCAPSSA ® NDA resubmitted to FDA ; PDUFA decision expected mid-2020 MYCAPSSA ® U.S. commercial launch planned for the fourth quarter of 2020 Top-line MYCAPSSA ® MPOWERED Phase 3 results on track for the fourth quarter of 2020 NEEDHAM, Mass. , Jan. 10, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc.

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent filings with the U.S. Securities and Exchange Commission.

Shareholder Tools